Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peginterferon alfa-2a plus tenofovir disoproxil fumarate in postpartum women with chronic hepatitis B
ChiCTR2000031665Phase 4Not yet recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Apr 2020
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of peginterferon alfa-2a and tenofovir disoproxil fumarate in Chronic Hepatitis B (CHB) (2 arms), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: HBeAg clearance rate at 48 weeks of treatment. Planned start Apr 2020; status: not yet recruiting.
02
Drugs
peginterferon alfa-2atenofovir disoproxil fumarate
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR2000031665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031665.